Ribonuclease (3.1.4) Patents (Class 435/199)
  • Patent number: 10538556
    Abstract: Simple ?-hairpin peptides in linear and cyclic form that specifically bind to HIV-1 Trans-Activation Response element (HIV-1 TAR), as well as compositions and use thereof are described.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: January 21, 2020
    Assignees: Colorado State University Research Foundation, University of Rochester
    Inventors: Brian R. McNaughton, David W. Crawford, Joseph E. Wedekind, Ivan A. Belashov
  • Patent number: 10457968
    Abstract: The present invention provides improved DNA polymerases, in particular, type A DNA polymerases, that may be better suited for applications in recombinant DNA technologies. Among other things, the present invention provides modified DNA polymerases derived from directed evolution experiments designed to select mutations that confer advantageous phenotypes under conditions used in industrial or research applications.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: October 29, 2019
    Assignee: Kapa Biosystems, Inc.
    Inventors: William Bourn, Maryke Appel, Gavin Rush, John Foskett, Paul McEwan
  • Patent number: 10435679
    Abstract: Methods of making mutant Cas9 proteins are described.
    Type: Grant
    Filed: October 11, 2018
    Date of Patent: October 8, 2019
    Assignee: President and Fellows of Harvard College
    Inventors: Alejandro Chavez, Frank J. Poelwijk, George M. Church
  • Patent number: 10351831
    Abstract: Fusion polypeptides having a heterologous 5?-3? exonuclease domain linked to a polymerase that does not naturally have 5?-3? exonuclease activity, as well as methods of their use are provided. Other aspects are also disclosed.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: July 16, 2019
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Yan Wang, Man Cheng
  • Patent number: 10323217
    Abstract: The disclosure concerns a detergent composition comprising one or more anionic surfactants; an enzyme selected from the group consisting of: a protease, a lipase, a cutinase, an amylase, a carbohydrase, a cellulase, a pectinase, a mannanase, an arabinase, a galactanase, a xylanase, and an oxidase; and a deoxyribonuclease (DNase), as well as methods for washing a textile.
    Type: Grant
    Filed: December 9, 2013
    Date of Patent: June 18, 2019
    Assignee: Novozymes A/S
    Inventors: Klaus Gori, Lilian Eva Tang Baltsen, Marie Allesen-Holm
  • Patent number: 10266851
    Abstract: Compositions and methods for using programmable DNA binding proteins to increase the efficiency and/or specificity of targeted genome modification or to facilitate the detection of specific genomic loci in eukaryotic cells.
    Type: Grant
    Filed: February 20, 2017
    Date of Patent: April 23, 2019
    Assignee: Sigma-Aldrich Co. LLC
    Inventor: Fuqiang Chen
  • Patent number: 10184121
    Abstract: Methods for screening pancrelipase for RNA virus contamination comprise removing free viral RNA from the pancrelipase, denaturing any viruses in the pancrelipase to release encapsidated RNA into the pancrelipase milieu, and detecting this released RNA. Removal of free viral RNA may comprise treating pancrelipase with RNase and DNase or precipitating the protein fraction of pancrelipase with a salt that precipitates the protein fraction while leaving nucleic acids such as RNA in solution. Pancrelipase substantially devoid of free nucleic acid is also provided.
    Type: Grant
    Filed: June 19, 2015
    Date of Patent: January 22, 2019
    Assignee: ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED
    Inventors: Giovanni Ortenzi, Luigi Ghidorsi
  • Patent number: 9952176
    Abstract: Apparatus and methods for size selecting nucleic acid molecules having wide range of applications including the production of DNA libraries for sequencing technologies. An automated high throughput system for size selection of multiple nucleic acid samples that uses imaging technique to detect the progress of a target fraction and feedback from the imaging to control electrophoresis. Predictive algorithms for timed nucleic acid extractions are generated to provide size selected nucleic acid molecules of required size ranges.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: April 24, 2018
    Assignee: British Columbia Cancer Agency Branch
    Inventors: Robin J. Noel Coope, Jared Raymond Slobodan
  • Patent number: 9856473
    Abstract: Disclosed herein are compounds, compositions and methods for modulating the expression of LMNA in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders. Further provided are methods of identifying cis splicing regulatory elements of a selected mRNA using the disclosed compounds.
    Type: Grant
    Filed: June 25, 2014
    Date of Patent: January 2, 2018
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: C. Frank Bennett, Kenneth W. Dobie, Susan M. Freier, Stanley T. Crooke, Timothy Vickers
  • Patent number: 9758796
    Abstract: The present invention is concerned with nuclease fusion proteins and various uses thereof. Specifically, it relates to a polynucleotide encoding a polypeptide comprising (i) a first module comprising at least a first DNA binding domain derived from a homing endonuclease, (ii) a linker, and (iii) a second module comprising at least a second DNA binding domain and a cleavage domain derived from a restriction endonuclease, wherein the polypeptide functionally interacts only with DNA comprising a DNA recognition site for the first DNA binding domain and a DNA recognition site for the second DNA binding domain, and wherein the cleavage domain cleaves DNA within a specific DNA cleavage site upon binding of the polypeptide. Further contemplated are a vector and a non-human transgenic organism comprising the polynucleotide as well as a polypeptide encoded by the polynucleotide of the invention.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: September 12, 2017
    Assignee: BASF PLANT SCIENCE COMPANY GMBH
    Inventors: Ines Fonfara, Wolfgang Wende, Alfred Pingoud
  • Patent number: 9675662
    Abstract: Compositions for inhibition of RNA Polymerase I include peptides of Rpa43. Methods of production and use thereof are also disclosed.
    Type: Grant
    Filed: December 2, 2011
    Date of Patent: June 13, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventor: Lawrence Rothblum
  • Patent number: 9567603
    Abstract: Methods for increasing specificity of RNA-guided genome editing, e.g., editing using CRISPR/Cas9 systems.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 14, 2017
    Assignee: The General Hospital Corporation
    Inventors: J. Keith Joung, Shengdar Tsai
  • Patent number: 9506110
    Abstract: A processing method to trim ends of DNA fragments, exposing the internal DNA part to give original DNA sequence information enabling application of next generation sequencing for DNA samples to be amplified by DOP-PCR or other primer dependent amplification methods. Specifically, nucleic acids are amplified using primers comprising a recognition site for a restriction enzyme, for example Bpml or Mmel. Primer sequences are removed by cleavage with the restriction enzyme.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: November 29, 2016
    Assignee: Agency for Science, Technology and Research
    Inventors: Masafumi Muratani, Huck Hui Ng
  • Patent number: 9491934
    Abstract: The present invention provides methods for modulating expression of endogenous cellular genes using recombinant zinc finger proteins.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: November 15, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: George Norbert Cox, III, Casey Christopher Case, Stephen P. Eisenberg, Eric Edward Jarvis, Sharon Kaye Spratt
  • Patent number: 9376689
    Abstract: Disclosed herein are engineered cleavage half-domains; fusion polypeptides comprising these engineered cleavage half-domains; polynucleotides encoding the engineered cleavage half-domains and fusion proteins; and cells comprising said polynucleotides and/or fusion proteins. Also described are methods of using these polypeptides and polynucleotides, for example for targeted cleavage of a genomic sequence.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: June 28, 2016
    Assignee: Sangamo BioSciences, Inc.
    Inventors: Yannick Doyon, Jeffrey C. Miller
  • Patent number: 9353358
    Abstract: The subject of the invention is the ribonuclease which cleaves RNA strand in DNA-RNA hybrids, wherein ribonuclease comprises fusion protein comprising catalytic domain of RNase HI (RNase HI) or derivative thereof with a zinc finger DNA-RNA hybrid binding domain, and wherein the zinc finger binding domain has the ability to bind to specific sequences in the DNA-RNA hybrid. The invention also relates to new methods for determination of the sequence preference of DNA-RNA hybrid binding protein(s) or its domain(s) and allows determining the sequence recognized by sequence specific binding protein in the DNA-RNA hybrid.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: May 31, 2016
    Assignee: MIEDZYNARODOWY INSTYTUT BIOLOGII MOLEKULARNEJ I KOMORKOWEJ
    Inventors: Janusz Marek Bujnicki, Agata Agnieszka Sulej, Krzysztof Jerzy Skowronek, Marcin Nowotny
  • Patent number: 9340835
    Abstract: The invention includes methods and apparatus for separating heteroduplexed nucleic acids from homoduplexed nucleic acids having similar sequences and being at a much higher concentration. The heteroduplexed nucleic acids may be separated through the application of a time varying driving field and a time-varying mobility field to a sample of heteroduplexed and homoduplexed nucleic acids in a separation medium. Once the heteroduplexed nucleic acids are isolated and recovered, it is straightforward to analyze the sequences of the heteroduplexed nucleic acids, e.g., using sequencing or hybrid assays.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: May 17, 2016
    Assignees: Boreal Genomics Corp., The University Of British Columbia
    Inventors: Andrea Marziali, Joel Pel
  • Patent number: 9217139
    Abstract: The purpose of the present invention is to provide a nuclease that secretes natural nonpathogenic microorganisms extracellularly, has higher specific activity than conventional nucleases, and is useful in nucleolytic degradation on an industrial scale. This purpose is achieved with an extracellularly secreted nuclease derived from Streptomyces bacteria, the nuclease having specific activity equal to or greater than the specific activity of Benzonase® when supplied to double-stranded DNA for 30 minutes at 37° C. in 20 mM Tris/HCl (pH 8.5) containing 1 mM MgCl2 and 1 mM CaCl2 after purification, using double-stranded DNA, single-stranded DNA, and RNA as substrates.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: December 22, 2015
    Assignee: JAPAN AGENCY FOR MARINE-EARTH SCIENCE AND TECHNOLOGY
    Inventors: Kozue Mori, Yukari Ohta, Yuji Hatada, Nobuyuki Nakamura, Masayuki Miyazaki
  • Patent number: 9200266
    Abstract: Disclosed herein are methods and compositions for generating a single-stranded break in a target sequence, which facilitates targeted integration of one or more exogenous sequences.
    Type: Grant
    Filed: March 6, 2014
    Date of Patent: December 1, 2015
    Assignee: Sangamo BioSciences, Inc.
    Inventor: Jianbin Wang
  • Patent number: 9034625
    Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: May 19, 2015
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Aine Quimby, Shuang-Yong Xu, Shengxi Guan, Hua Wei, Penghua Zhang, Dapeng Sun, Siu-hong Chan
  • Patent number: 9023634
    Abstract: Compositions and methods are provided for enzymes with altered properties that involve a systematic approach to mutagenesis and a screening assay that permits selection of the desired proteins. Embodiments of the method are particularly suited for modifying specific properties of restriction endonucleases such as star activity. The compositions includes restriction endonucleases with reduced star activity as defined by an overall fidelity index improvement factor.
    Type: Grant
    Filed: January 8, 2013
    Date of Patent: May 5, 2015
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Aine Quimby, Shuang-Yong Xu, Shengxi Guan, Hua Wei, Penghua Zhang, Dapeng Sun, Siu-hong Chan
  • Publication number: 20150105315
    Abstract: The present invention relates to polypeptide fragments comprising an amino-terminal fragment of the PA subunit of a viral RNA-dependent RNA polymerase or variants thereof possessing endonuclease activity, wherein said PA subunit is from a virus belonging to the Orthomyxoviridae family. This invention also relates to (i) crystals of the polypeptide fragments which are suitable for structure determination of said polypeptide fragments using X-ray crystallography and (ii) computational methods using the structural coordinates of said polypeptide to screen for and design compounds that modulate, preferably inhibit the endonucleolytically active site within the polypeptide fragment. In addition, this invention relates to methods identifying compounds that bind to the PA polypeptide fragments possessing endonuclease activity and preferably inhibit said endonucleolytic activity, preferably in a high throughput setting.
    Type: Application
    Filed: October 21, 2014
    Publication date: April 16, 2015
    Applicants: EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL), UNIVERSITY JOSEPH FOURIER FILIALE, Centre National de la Recherche Scientifique - Direction de la Politique Industrielle
    Inventors: Denis Bouvier, Thibaut Crepin, Rob Ruigrok, Alexander Dias, Stephen Cusack
  • Patent number: 9006407
    Abstract: The present invention relates to the use of ribonucleases (RNases) in the treatment or prevention of disease.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: April 14, 2015
    Assignee: Quintessence Biosciences, Inc.
    Inventors: Tony Klink, John Kink, Laura Strong
  • Publication number: 20150099290
    Abstract: Methods are provided for engineering non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins. Non-naturally occurring proteins comprising artificial pH-sensitive conformational switches that respond to a change in pH by causing a global unfolding of the proteins are also provided.
    Type: Application
    Filed: October 6, 2014
    Publication date: April 9, 2015
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Bertrand E. Garcia-Moreno, Aaron Robinson
  • Patent number: 8999641
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: March 26, 2014
    Date of Patent: April 7, 2015
    Assignees: The Broad Institute Inc., Maassachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana
  • Publication number: 20150093802
    Abstract: The present invention provides new zinc finger proteins and zinc finger nuclease (ZFNs) that find particular using in repairing the cystic fibrosis transmembrane conductance regulator (CFTR) gene.
    Type: Application
    Filed: September 30, 2014
    Publication date: April 2, 2015
    Applicants: UNIVERSITY OF IOWA RESEARCH FOUNDATION, THE GENERAL HOSPITAL CORPORATION D/B/A MASSACHUSETTS GENERAL HOSPITAL
    Inventors: Paul MCCRAY, Morgan MAEDER, Jae Keith JOUNG
  • Publication number: 20150094209
    Abstract: The present invention provides autonomous replication sequences (ARSs) isolated from Nannochloropsis that support the replication of episomal DNA molecules (EDMs) in eukaryotic cells. The ARSs and EDMs provided herein can be used for expressing genes in organisms including algae and heterokonts.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 2, 2015
    Applicant: Synthetic Genomics, Inc.
    Inventors: Peter DeHoff, Leah Soriaga, Srividya Akella
  • Patent number: 8993233
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors with additional functional domains. Also provided are methods of directing CRISPR complex formation in prokaryotic and eukaryotic cells to ensure enhanced specificity for target recognition and avoidance of toxicity.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: March 31, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Feng Zhang, Le Cong, Randall Jeffrey Platt, Neville Espi Sanjana, Fei Ran
  • Publication number: 20150079064
    Abstract: Disclosed herein are transcription activator-like effector nuclease (TALEN)-related compositions and methods of using said TALENs for correcting mutant genes.
    Type: Application
    Filed: April 26, 2013
    Publication date: March 19, 2015
    Applicant: Duke University
    Inventors: Charles Gersbach, David Ousterout
  • Publication number: 20150079633
    Abstract: The present invention relates to lower eukaryotic host cells having modified oligosaccharides which may be modified further by heterologous expression of a set of glycosyltransferases, sugar and sugar nucleotide transporters to become host-strains for the production of mammalian, e.g., human therapeutic glycoproteins. The process provides an engineered host cell which can be used to express and target any desirable gene(s) involved in glycosylation. Host cells with modified lipid-linked oligosaccharides are created or selected. N-glycans made in the engineered host cells exhibit GnTIV, GnTV, GnT VI or GnTIX activity, which produce multiantennary N-glycan structures and may be modified further by heterologous expression of one or more enzymes, e.g., glycosyltransferases, sugar, sugar nucleotide transporters, to yield human-like glycoproteins. For the production of therapeutic proteins, this method may be adapted to engineer cell lines in which any desired glycosylation structure may be obtained.
    Type: Application
    Filed: July 25, 2014
    Publication date: March 19, 2015
    Inventors: Piotr Bobrowicz, Stephen R. Hamilton, Tillman U. Gerngross, Stefan Wildt, Byung-Kwon Choi, Juergen Hermann Nett, Robert C. Davidson
  • Patent number: 8969061
    Abstract: Compositions, methods and a kit are described relating to a novel family of enzymes which preferentially bind to a hydroxymethylated cytosine or a glucosylated hydroxymethylated cytosine and cleave double-stranded DNA at a defined distance 3? of the recognition site to produce a cleavage fragment with a 1-3 base overhang.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: March 3, 2015
    Assignee: New England Biolabs, Inc.
    Inventors: Zhenyu Zhu, Yu Zheng, Shengxi Guan, Hua Wang, Aine Quimby, Penghua Zhang, Lynne Apone
  • Publication number: 20150037842
    Abstract: The disclosure relates to a Gram negative bacterial cell that is transformed with a nucleic acid molecule that encodes a Gram positive twin-arginine translocase and including methods for the production of polypeptides.
    Type: Application
    Filed: February 22, 2013
    Publication date: February 5, 2015
    Inventor: Colin Robinson
  • Publication number: 20150040252
    Abstract: The invention relates to isolation of novel ?-actin and ribosomal protein S21 (rpS21) promoters and uses thereof. In particular, this invention features nucleotide sequences for rodent ?-actin promoters including, hamster, rat, and mouse, and hamster rpS21 promoter.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Applicant: GENZYME CORPORATION
    Inventors: Scott D. ESTES, Weiqun ZHANG
  • Patent number: 8945839
    Abstract: The invention provides for systems, methods, and compositions for altering expression of target gene sequences and related gene products. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for utilizing the CRISPR-Cas system.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: February 3, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Publication number: 20150017728
    Abstract: The present invention provides compositions and methods for targeted cleavage of cellular chromatin in a region of interest and/or homologous recombination at a predetermined site in cells. Compositions include fusion polypeptides comprising a TAL effector binding or a zinc finger domain and an I-TevI homing endonuclease cleavage domain as well as nucleic acid sequence encoding the same. The use of the I-TevI domain allows for monomer endonuclease sequences to achieve cleavage of cellular chromatin and represents an advantage over prior endonucleases which require self-dimerization, and two nucleases with appropriate spacers.
    Type: Application
    Filed: September 19, 2012
    Publication date: January 15, 2015
    Inventors: Bing Yang, Ting Li, Sheng Huang
  • Patent number: 8932814
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: January 13, 2015
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Le Cong, Feng Zhang
  • Publication number: 20150010982
    Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.
    Type: Application
    Filed: September 17, 2014
    Publication date: January 8, 2015
    Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
  • Patent number: 8911948
    Abstract: The present invention pertains to novel oligonucleotide compounds for use in various biological assays, such as nucleic acid amplification, ligation and sequencing reactions. The novel oligonucleotides comprise a ribonucleic acid domain and a blocking group at or near the 3? end of the oligonucleotide. These compounds offer an added level of specificity previously unseen. Methods for performing nucleic acid amplification, ligation and sequencing are also provided. Additionally, kits containing the oligonucleotides are also disclosed herein.
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: December 16, 2014
    Assignee: Integrated DNA Technologies, Inc.
    Inventors: Joseph Alan Walder, Mark Aaron Behlke, Scott Rose, Joseph Dobosy
  • Publication number: 20140363561
    Abstract: The invention relates to methods for stably integrating a desired polynucleotide into a plant genome.
    Type: Application
    Filed: March 14, 2014
    Publication date: December 11, 2014
    Applicant: J.R. SIMPLOT COMPANY
    Inventors: CAIUS M. ROMMENS, HUI DUAN, J. TROY WEEKS
  • Publication number: 20140356960
    Abstract: The present invention relates to a nucleic acid containing at least one homing endonuclease site (HE) and at least one restriction enzyme site (X) wherein the HE and X sites are selected such that HE and X result in compatible cohesive ends when cut by the homing endonuclease and restriction enzyme, respectively, and the ligation product of HE and X cohesive ends can neither be cleaved by the homing endonuclease nor by the restriction enzyme. Further subject-matter of the present invention relates to a vector comprising the nucleic acid of the present invention, host cells containing the nucleic acid and/or the vector; a kit for cloning and/or expression of multiprotein complexes making use of the vector and the host cells, a method for producing a vector containing multiple expression cassettes, and a method for producing multiprotein complexes.
    Type: Application
    Filed: April 25, 2014
    Publication date: December 4, 2014
    Inventor: Imre Berger
  • Publication number: 20140359798
    Abstract: Genetically engineered mice having a corrected Cbr1rd8 mutation and methods for correcting the Cbr1rd8 mutation to produce the genetically engineered mice are provided according to aspects of the present invention. Kits, expression vectors and fusion proteins according to aspects of the invention are provided for use to produce the genetically engineered mice characterized by a corrected Cbr1rd8 mutation.
    Type: Application
    Filed: June 3, 2014
    Publication date: December 4, 2014
    Applicant: THE JACKSON LABORATORY
    Inventors: Michael V. Wiles, Benjamin E. Low
  • Publication number: 20140342400
    Abstract: The present invention relates to an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1. The present invention also relates to a method for increasing expression of a target protein using the peptide consisting of the amino acid sequence of SEQ ID NO: 1, comprising (a) fusing the peptide with the target protein to form a recombinant protein; and (b) expressing the recombinant protein by an expression host.
    Type: Application
    Filed: May 13, 2014
    Publication date: November 20, 2014
    Applicant: NATIONAL TSING HUA UNIVERSITY
    Inventor: Margaret Dah-Tsyr Chang
  • Patent number: 8889356
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: February 18, 2014
    Date of Patent: November 18, 2014
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology
    Inventor: Feng Zhang
  • Patent number: 8889394
    Abstract: Described herein are methods and compositions for generating and using fusion proteins.
    Type: Grant
    Filed: September 7, 2009
    Date of Patent: November 18, 2014
    Assignee: Empire Technology Development LLC
    Inventor: Sreekanth H. Chalasani
  • Publication number: 20140335593
    Abstract: This invention relates to altered forms of members of the RNase A superfamily. An RNase A can be modified to be cytotoxic by altering its amino acid sequence so that it is not bound easily by the ribonuclease inhibitor while still retaining catalytic properties. While earlier work had identified some modifications to RNase A that would result in cytotoxicity, the use of the FADE algorithm for molecular interaction analysis has led to several other locations that were candidates for modification. Some of those modifications did result in RNase A variants with increase cytotoxicity.
    Type: Application
    Filed: July 18, 2014
    Publication date: November 13, 2014
    Inventors: Ronald Raines, Julie C. Mitchell, Thomas J. Rutkoski
  • Publication number: 20140329233
    Abstract: Methods and kits for joining two or more polynucleotides to form a product polynucleotide are provided. A mixture contains a first polynucleotide comprising a selectable marker. The mixture further contains a second polynucleotide comprising a first typeIIs recognition sequence and a second typeIIs recognition sequence. The second polynucleotide is other than the first polynucleotide. The mixture further contains a first typeIIs restriction endonuclease that cleaves the first typeIIs recognition sequence to produce a first end, a second typeIIs restriction endonuclease that cleaves the second typeIIs recognition sequence to produce a second end, and a DNA ligase. The first end is not compatible with the second end. The combined actions of the enzymes in the mixture join the first polynucleotide to the second polynucleotide forming a product polynucleotide, which is obtained by transforming the mixture into a host cell.
    Type: Application
    Filed: May 1, 2013
    Publication date: November 6, 2014
    Applicant: DNA Twopointo, Inc.
    Inventors: Jeremy Minshull, Jon Ness, Elias Theodorou
  • Patent number: 8871445
    Abstract: The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system.
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: October 28, 2014
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College
    Inventors: Le Cong, Feng Zhang
  • Patent number: 8865406
    Abstract: The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: October 21, 2014
    Assignees: The Broad Institute Inc., Massachusetts Institute of Technology
    Inventors: Feng Zhang, Fei Ran
  • Patent number: 8859266
    Abstract: The present disclosure encompasses systems, and their methods of use, for detecting a target analyte. The systems include a first and second oligonucleotide probe that associate together to form a complex that binds to a target analyte; a cleavable reporter molecule that binds to the complex; and cleaving agent.
    Type: Grant
    Filed: April 28, 2011
    Date of Patent: October 14, 2014
    Assignee: University of Central Florida Research Foundation, Inc.
    Inventors: Yuliva V. Gerasimova, Dmitry M. Kolpashchikov
  • Publication number: 20140302563
    Abstract: The present disclosure provides nucleic acids encoding an RNA recognition sequence positioned proximal to an insertion site for the insertion of a sequence of interest; and host cells genetically modified with the nucleic acids. The present disclosure also provides methods of modifying the activity of a target RNA, and kits and compositions for carrying out the methods.
    Type: Application
    Filed: April 9, 2014
    Publication date: October 9, 2014
    Applicant: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Lei S. Qi, Rachel E. Haurwitz, Adam P. Arkin